Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| IXHL | Incannex Healthcare | $3.08 | -$2.89 | -48.41% | 4.5M | $69M | $2.40$49.80 |
| NOA | North American Construction Group | $12.10 | -$4.65 | -27.76% | 34.2K | $479M | $12.08$18.24 |
| RHLD | Resolute Management | $115.26 | -$38.42 | -25.00% | 15.4K | $1.3B | $24.22$236.19 |
| SRI | Stoneridge | $5.96 | -$1.71 | -22.26% | 32.4K | $215M | $3.54$9.71 |
| RPID | Rapid Micro Biosystems | $3.42 | -$0.96 | -21.92% | 10.8K | $194M | $1.86$4.94 |
| NTSK | Netskope | $9.55 | -$2.58 | -21.27% | 20.8M | $4.8B | $8.81$27.99 |
| CRMT | America's Car-Mart | $15.17 | -$3.88 | -20.37% | 25.9K | $158M | $14.58$62.72 |
| SEV | Aptera Motors | $2.75 | -$0.68 | -19.82% | 1.8M | $111M | $1.29$40.85 |
| SNBR | Sleep Number | $3.70 | -$0.89 | -19.39% | 207.4K | $105M | $3.49$13.94 |
| PLYX | Polaryx Therapeutics | $4.65 | -$1.11 | -19.27% | 991.4K | $273M | $2.20$48.91 |
| ZNB | Zeta Network Group | $8.71 | -$2.07 | -19.20% | 68.5K | $1.6B | $7.52$2,800.00 |
| GEMG | Themes ETF Trust - Leverage Shares 2x Long Gemi Daily ETF | $2.03 | -$0.47 | -18.68% | 168.8K | - | $1.13$17.73 |
| IPX | IperionX | $40.42 | -$9.19 | -18.52% | 21.1K | $1.7B | $12.28$61.45 |
| FGL | Founder Group | $5.15 | -$1.17 | -18.51% | 46.5K | $107M | $5.15$155.00 |
| SST | System1 | $2.10 | -$0.43 | -17.00% | 85.3K | $21M | $1.95$15.00 |
| ACXP | Acurx Pharmaceuticals | $5.01 | -$1.02 | -16.91% | 6.6M | $15M | $1.33$21.00 |
| PSNL | Personalis | $6.63 | -$1.32 | -16.60% | 136.2K | $832M | $2.83$11.50 |
| AGCC | Agencia Comercial Spirits | $15.63 | -$3.06 | -16.37% | 498.9K | $642M | $3.66$24.98 |
| AAOI | Applied Optoelectronics | $106.29 | -$20.72 | -16.31% | 568.1K | $9.6B | $9.71$128.96 |
| FEIM | Frequency Electronics | $46.36 | -$8.96 | -16.20% | 29.8K | $541M | $13.69$61.47 |
| HERE | Here Group | $3.74 | -$0.72 | -16.14% | 7.3K | $168M | $2.50$15.64 |
| IOVA | Iovance Biotherapeutics | $4.06 | -$0.78 | -16.12% | 719.2K | $2.0B | $1.64$5.63 |
| RVNL | GraniteShares ETF Trust - GraniteShares 2x Long Rivn Daily ETF | $30.38 | -$5.66 | -15.71% | 54.1K | - | $24.49$75.17 |
| ALOY | REalloys | $14.22 | -$2.65 | -15.71% | 1.7M | $76M | $2.60$26.90 |
| VEON | Veon | $45.20 | -$8.08 | -15.16% | 11K | $3.7B | $34.55$64.00 |
| KEQU | Kewaunee Scientific | $35.62 | -$5.36 | -13.08% | 56.9K | $117M | $30.33$60.89 |
Related Articles
Featured Article
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
David Jagielski, CPA|Nov 11, 2025
Iovance has a long way to go to get to a break-even point, but the company has been showing progress.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
Prosper Junior Bakiny|Nov 7, 2025
Wall Street may be overestimating these companies' potential.
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Prosper Junior Bakiny|Oct 17, 2025
Is there a glimmer of hope for either of these underperforming healthcare companies?
Can This Beaten-Down Stock Bounce Back?
Prosper Junior Bakiny|Sep 19, 2025
This biotech company is innovative, but the market demands more than that.
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
Eric Volkman|Aug 27, 2025
The company hasn't been popular among investors since winning its first FDA approval more than a year ago.
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
Prosper Junior Bakiny|Aug 24, 2025
Time is running out for the company to mount a comeback.
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
James Brumley|Aug 9, 2025
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.
Is Iovance Biotherapeutics Stock Due for a Big Rally?
David Jagielski, CPA|Jul 30, 2025
The biotech stock has been picking up steam of late -- but will it last?
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Cory Renauer|Jul 29, 2025
Even the average price estimate for this stock suggests it can soar, but not everyone's convinced.
